Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.

Inclusion criteria

• Tumor type: proven adenocarcinoma of the colon
• Extent of disease (AJCC 7th edition): clinically node negative (stage II) non-metastatic colon cancer
• Locally resectable disease
• Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent
• Laboratory data

• Serum creatinine ≤ 1.5 mg/dl or a calculated GFR ≥ 60 mL/min/1.73 m2
• Serum total bilirubin ≤ 1.5 mg/dl, except for known Gilbert's disease
• Platelet count > 100,000/µl
• Hemoglobin > 9g/dl
• Neutrophil granulocytes > 1,500/ml
• International Normalized Ratio (INR) ≤ 2
• Absence of alcohol and/or drug abuse
• No inclusion in other clinical trials interfering with the study protocol
• No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy
• Absence of any severe organ insufficiency
• No pregnancy or breast feeding
• Adequate contraception in fertile patients
• Written informed consent

Exclusion criteria

• Node positive and/or metastatic disease
• Locally unresectable disease
• Medically unfit patients (Karnofsky index < 70%)
• Allergies to any of the procedural substances (allergy to iodides, hypersensitivity to products containing human albumin)